Overview of Perfan

Quick Facts: Perfan (Enoximone)

Property	Description
Active ingredient	Enoximone
Form	Solution for injection (Intravenous)
Pharmacological class	Inodilator (Positive inotrope + Vasodilator)
General purpose	Critical circulatory support
Origin	Synthetic (Imidazolidinone derivative)

What is Perfan and Its Chemical Identity?

Perfan is the trade name for the active chemical substance Enoximone, a synthetic compound used to support heart function. Enoximone is a single-ingredient cardiovascular agent, chemically derived from the imidazolidinone structure. This synthetic origin ensures a precise pharmacological profile, distinguishing it from naturally derived agents and affirming its specialized role in critical clinical care settings.

What Type of Drug is Enoximone (Perfan)?

Enoximone is classified as an inodilator, a specialized pharmacological class that performs a dual action on the cardiovascular system. It provides a positive inotropic effect, which increases the force of the heart's contraction, combined with vasodilation, which helps widen blood vessels. This balanced functionality provides significant hemodynamic support. Unlike single-action agents, the inodilator effect is reserved for acute interventions, confirming its status as a high-potency medicine used for hospitalized patients requiring intensive circulatory assistance.

What is the General Purpose and Form of Perfan?

The general purpose of this medicine is to provide critical circulatory support when the heart is severely compromised and cannot effectively move blood, such as during an acute cardiac event. This agent is prepared as a sterile solution for injection and is administered exclusively via the intravenous (I.V.) route. This specific dosage form is essential, as the I.V. route ensures immediate therapeutic availability, a necessity for rapid intervention.

What side effects are possible with Perfan?

Possible Side Effects and Safety Information

The safety profile of the active ingredient in Perfan (perampanel, a non-competitive AMPA glutamate receptor antagonist) is based on clinical trials and regulatory surveillance reports, identifying specific risks and common adverse reactions.

Serious and Clinically Significant Risks

Serious Psychiatric and Behavioral Reactions: The drug carries a Warning for serious, potentially life-threatening psychiatric and behavioral events, including aggression, hostility, irritability, anger, and homicidal ideation/threats. Monitoring is required, especially during the initial titration phase and with dose increases, or at higher doses. Discontinuation is warranted if symptoms are severe or worsening.
Suicidal Behavior and Ideation: Like all Antiepileptic Drugs (AEDs), this medication increases the risk of suicidal thoughts or behavior. All patients must be monitored for new or worsening depression and unusual changes in mood or behavior.
Withdrawal Seizures: Abrupt discontinuation of the medication in patients with epilepsy may lead to an increase in seizure frequency.

Common Adverse Reactions

The most commonly reported side effects (occurring in ge 5% of patients) are primarily related to the nervous system and include dizziness, somnolence (sleepiness), fatigue, and gait disturbance (problems with walking). Other frequent reactions include irritability, nausea, and falls.

Safety Restrictions and Monitoring

Neurologic Impairment: Patients should exercise caution when driving or operating heavy machinery due to the risk of dizziness and somnolence.
Alcohol Use: Concomitant use with alcohol significantly worsens mood and may increase anger, and should be avoided.
Drug Interactions: A dose of 12 mg once daily may reduce the effectiveness of hormonal contraceptives.
High-Risk Populations: Caution and dose adjustment may be necessary for patients with mild to moderate hepatic impairment; the drug is generally not recommended for those with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

A Perfan (Enoximone) overdose is officially documented as an exaggeration of the drug’s pharmacological effects. The primary documented clinical manifestations reflect severe hemodynamic instability, specifically severe hypotension (excessively low blood pressure) and a rapid heart rate known as cardiac tachycardia. The overdose profile also includes potential gastrointestinal disturbances. The most serious or life-threatening outcomes, as stated in regulatory documents, involve profound cardiovascular collapse and the occurrence of sustained ventricular arrhythmias.

In the event of a known or strongly suspected overdose, emergency medical care is required immediately, and patients must seek immediate medical attention or contact emergency services. Regulator-mandated action requires the immediate discontinuation of the drug infusion. Management is strictly limited to symptomatic and supportive treatment, as official information confirms that no specific antidote is known to reverse the effects of Enoximone. Treatment procedures mandate continuous observation, including continuous hemodynamic and ECG monitoring, along with aggressive measures for the correction of severe hypotension, such as fluid management or the careful use of vasopressors. This structure ensures that users understand the high-risk nature of the overdose and the required, regulator-mandated emergency steps.

Therapeutic Uses of Perfan

What Perfan Treats: Main Uses and Benefits

Perfan is primarily used to provide supportive therapeutic benefit during acute symptomatic episodes in conditions characterized by periods of heightened symptoms, such as certain advanced stages of congestive heart failure. The medication is considered relevant for managing severe, symptomatic manifestations associated with these conditions.

The medicine is commonly used to help with symptoms that interfere with daily functioning and create noticeable physiological strain. It is applied across domains where additional symptomatic support is needed, particularly when symptoms become temporarily overwhelming. These applications involve easing manifestations linked to heart failure, including acute shortness of breath and fluid overload distress.

It is applied in scenarios where additional management of discomfort is required during phases when symptoms become more noticeable. This support contributes to easing the overall symptom load during acute, disruptive episodes.

Quick Fact: Relief for Symptoms of Acute Discomfort

Quick Fact: Relief for symptoms related to physical discomfort during acute episodes. It is commonly used when short-term symptomatic assistance is needed during phases when symptoms become more noticeable.

Regulatory References

U.S. National Institutes of Health (NIH) clinical trial register

Eligibility and Restrictions for Use

Who Can and Cannot Use Perfan (Enoximone)?

Official regulatory documents define specific eligibility rules for Perfan, focusing on absolute contraindications and population restrictions based on physical status and comorbidities.

Contraindicated and Restricted Populations

Classification	Population or Condition
Absolute Contraindication	Patients with known hypersensitivity to enoximone or any of the medicinal product's components.
Use Not Recommended	Women who are breastfeeding infants due to the unknown risk of excretion into human milk.
Use Restricted/Caution	Patients with renal dysfunction (creatinine clearance below 40 ml/min) due to reduced drug clearance and risk of accumulation.
Comorbidity Caution	Patients with congestive cardiac failure associated with blood platelet counts below 100 imes 10^6/ L.

Age and Reproductive Status

Perfan is primarily intended for adult patients receiving short-term treatment for congestive cardiac failure. Pediatric use for this specific intravenous indication is generally not established. Use during pregnancy is permitted only if the potential benefit justifies the potential risk, as stated in regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Perfan (Enoximone) as established in authoritative government regulatory documents, focusing on administration constraints and specific co-administration findings.

Documented Interaction Patterns

Interaction Type	Officially Documented Statement
Administration Incompatibility	Other drugs or fluids must not be mixed in the same container or administered concomitantly in the same infusion line as Enoximone solution.
Diluent Restriction	Glucose solutions are restricted from use as a diluent due to documented physical incompatibility that may lead to the formation of crystals.
Clinically Insignificant Interaction	Official regulatory data confirms the lack of untoward clinical drug interaction when Enoximone was co-administered with specific cardiovascular agents, including Digitalis Glycosides (such as Digoxin) and various Diuretics (including Amiloride, Furosemide, and Spironolactone).

Interaction Classification Summary

Enoximone's regulatory interaction profile is defined primarily by constraints related to physical and chemical incompatibility during intravenous administration. This includes mandatory procedural restrictions on the co-administration of other intravenous medications in the same line and the prohibition of specific diluents. Furthermore, the profile includes formal statements on the absence of significant interaction effects with specific cardiac co-medications, without explicitly detailing metabolic or transporter-mediated interaction mechanisms.

Mechanism of Action

Molecular Action: Targeting the PDE3 Enzyme

Perfan (Enoximone) exerts its primary mechanism by acting as a selective inhibitor of the phosphodiesterase type III (PDE3) enzyme. This enzyme hydrolyzes the second messenger cyclic AMP (cAMP); by blocking this process, the drug causes an accumulation of cAMP inside both cardiac myocytes and vascular smooth muscle cells.

Dual Physiological Effect: Inotropy and Vasodilation

The resulting increase in cAMP triggers distinct, yet simultaneous, functional changes. In the heart, it activates a cascade that enhances calcium ( Ca^2+) handling, resulting in a greater force of contraction (positive inotropy). Concurrently, in the blood vessels, the same mechanism causes smooth muscle relaxation, leading to widespread vasodilation and a reduction in systemic resistance.

Hemodynamic Consequence and Mechanism Limitation

The coordinated increase in the heart's pumping strength and the simultaneous reduction of resistance collectively increase the cardiac output. However, this mechanism of increasing Ca^2+ availability inherently escalates the heart muscle’s oxygen consumption, which is a mechanistic outcome associated with this class of action.

Dosage and Administration Information

Perfan (Enoximone) is administered exclusively via the intravenous (I.V.) route as an injection or infusion, intended for short-term support in a specialized clinical environment. In preparation for administration, the 5 mg/ml solution must be diluted 1:1 with either 0.9% sodium chloride injection or water for injections to achieve a standardized concentration of 2.5 mg/ml. Solutions that are more dilute than 2.5 mg/ml should not be used, as this may lead to crystallization.

The adult dosing regimen typically begins with a loading dose of 0.5 mg/kg administered slowly at a rate that does not exceed 12.5 mg/minute. This initial bolus may be repeated once after 30 minutes if deemed necessary by the supervising clinician. Following the initial dose, administration continues either through a continuous infusion in the range of 2.5 to 5 micrograms/kg/minute or via a repeated intermittent bolus of 0.5 mg/kg given every 4 to 8 hours. The continuous infusion rate is subject to adjustment and should be maintained at the lowest effective dose throughout the period of use.

For patients with established renal impairment where creatinine clearance is less than 40 ml/min, the intermittent bolus regimen is utilized instead of continuous infusion. This modification addresses the slower clearance rate observed in this specific patient population.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Pharmacological Profile

Research has explored the drug’s pharmacological profile, which includes affecting the excitability of nerve endings. Studies assessed whether this mechanism was correlated with changes in reported discomfort and seizure frequency. The complete mechanism of action across all studied conditions remains under investigation.

Neuropathic Pain Studies

Clinical trials investigated outcomes in chronic neuropathic pain, specifically in postherpetic neuralgia and diabetic peripheral neuropathy.

Study Design: Multiple randomized, double-blind, placebo-controlled trials were conducted, generally involving adults with confirmed diagnoses.
Key Findings: Findings indicated differences when compared to placebo on standardized pain measures (such as the VAS scale). Pooled analyses also evaluated the onset of potential changes in discomfort levels.
Duration of Trials: Primary registration studies typically spanned 8 to 12 weeks. Longer-term extension studies assessed changes in pain metrics over time.

Epilepsy Studies

Studies examined the drug as adjunctive therapy for partial-onset seizures in adult patients.

Study Design: Clinical trials included adult patients refractory to existing antiepileptic treatments. Regarding administration, trial protocols indicated administration with food.
Key Findings: Studies tracked changes in seizure frequency over the trial period in the active treatment groups compared to control groups. Research also monitored the percentage of participants who experienced a 50% or greater change in seizure frequency.

Fibromyalgia and Specialized Population Research

Early research investigated the drug’s potential role in managing fibromyalgia symptoms, focusing on global pain and sleep disturbance. Studies explored the drug’s profile in participants with mild to moderate renal impairment to assess tolerability and pharmacokinetics in this group.

Combination Therapy

Research examined whether the combination was associated with changes in quality of life metrics when added to certain standard-of-care treatments for chronic pain conditions. Data remain sparse regarding the long-term outcomes of this combination.

Frequently Asked Questions (FAQ)

Common questions about Perfan (FAQ)

Q: What are the most commonly reported side effects of Perfan?

A: According to official regulatory documents, reported undesirable effects include certain heart rhythm changes (arrhythmias), low blood pressure (hypotension), headache, and sleep disturbances like insomnia. Other reported effects relate to the digestive system, such as nausea, vomiting, or diarrhea. The clinical team monitors these effects closely in a hospital setting.

Q: How long does it usually take for Perfan to start showing an effect?

A: Official product information indicates that the effects of Perfan are usually noticeable relatively quickly due to its intravenous administration. Peak response, meaning when the drug is working at its strongest, is typically observed within 30 minutes following the initial loading dose.

Q: Can Perfan be used by patients who have known liver problems?

A: Regulatory information indicates that caution is necessary when the drug is administered to patients with known liver conditions. Changes in liver function tests have been observed, and official guidance states that hepatic (liver) function must be monitored regularly during treatment.

Q: Are the effects of Perfan noticeable right away or gradually over time?

A: Perfan is administered for acute cardiac support, and its effects are designed to be immediate. Official product information indicates that the therapeutic effect is usually noticeable, with peak response occurring within 30 minutes after the initial loading dose.

Q: What is the standard duration of action for a single dose of Perfan?

A: Official pharmacological data indicates that the active ingredient, Enoximone, has an elimination half-life of approximately 4 to 10 hours. The half-life refers to the time it takes for half of the drug to be eliminated from the body, providing an estimate of its overall duration of systemic exposure.

Q: Does Perfan have a safety warning regarding driving or operating machinery?

A: The official safety information states that warnings regarding driving or operating machinery are considered 'not applicable' for this medicine. This is because Perfan is strictly intended for use on patients who are hospitalized and receiving continuous clinical support.

Q: Are there any restrictions on Perfan use for people over 65?

A: The regulatory product information does not list a specific restriction or special warning for patients over 65 years of age receiving this intravenous treatment. The drug is primarily intended for short-term support in a controlled hospital environment.

Q: What does the official research evidence suggest about Perfan's effectiveness?

A: Official product information states that the drug is indicated for the treatment of congestive cardiac failure. Regulatory evidence indicates that a loading dose often produces an increase in the heart's pumping strength (cardiac index) of at least 25%.

Q: Why do some patient communities refer to Perfan as a 'life-saver'?

A: Perfan is indicated for use as critical circulatory support during acute heart failure, which is a serious medical condition. The drug's specialized role in providing immediate, high-potency assistance to a severely compromised heart explains why it is informally referred to using such strong terms.

Q: Is Perfan considered safe for use during pregnancy or breastfeeding?

A: Official regulatory documents advise that use during pregnancy is allowed only if the potential benefit is deemed to outweigh the potential risk. Furthermore, use in women who are breastfeeding is not recommended due to the unknown risk of the drug being excreted into human milk.

Q: What are the signs of a potential severe interaction with Perfan?

A: Regulatory guidance emphasizes the need for close monitoring during treatment due to the risk of significant changes in the heart's electrical rhythm (ECG) and blood pressure. These parameters are continuously checked by healthcare professionals as they are key indicators of the drug's activity and potential complications.

Q: Is it common to have mild headaches when first starting Perfan?

A: Yes, official regulatory documents list headache as an undesirable effect of the drug. Because this medication is administered in a hospital, any new or worsening symptoms, including a headache, are monitored by the supervising clinical team.

Q: Does Perfan work by lowering blood pressure?

A: Official safety information lists hypotension (low blood pressure) as a potential undesirable effect. Since the drug is known to cause vasodilation (widening of blood vessels), monitoring of blood pressure is a mandatory part of the administration process to ensure it remains stable.

Q: Is Perfan a medication that needs to be taken indefinitely for the condition?

A: Official regulatory documents clearly state that Perfan is indicated for the short-term treatment of acute congestive cardiac failure. It is used for immediate circulatory support in a critical care setting and is not intended to be a preventative or long-term medication.

Q: What general information is available on how Perfan is processed by the body (pharmacokinetics)?

A: Official pharmacological data indicates how the body processes the drug. The active ingredient is mainly eliminated through the kidneys and metabolized (broken down) by the liver through a process called hepatic oxidation.

Q: Are there specific routine lab tests required before starting Perfan?

A: According to the official prescribing information, certain lab parameters are required to be monitored regularly during treatment. This includes checking platelet counts and monitoring both hepatic (liver) and renal (kidney) function.

Q: What is the official guidance for managing minor side effects of Perfan?

A: The official guidance for managing significant side effects focuses on circulatory parameters. For example, if symptomatic hypotension (low blood pressure with symptoms) is observed, the drug's administration rate may be reduced or discontinued by the clinical team.

Q: Why is Perfan only available with a prescription?

A: Perfan is a prescription-only medicine because its use is restricted to hospitalized patients who require critical circulatory support. The official guidelines mandate continuous monitoring of the patient's heart rhythm and blood pressure during the entire course of therapy.

Q: Is Perfan used to prevent long-term complications related to its main use?

A: The regulatory documents state that the drug is indicated for short-term treatment of congestive cardiac failure. It is used for acute intervention and is not a medication intended for the prevention of long-term complications.

Q: Does Perfan affect mental clarity or concentration?

A: Official regulatory documents list insomnia (sleeplessness) as an undesirable effect, which is a symptom related to the central nervous system. Any potential effect on mental clarity or concentration would be monitored by the clinical team.

Q: Why are there different strengths or doses of Perfan available?

A: The specific preparation and strength of the medicine is designed to meet the complex dosing needs of the patient. The regimen requires various administration methods, including an initial high dose (loading dose) followed by either intermittent boluses or a continuous, adjustable rate infusion.

How should Perfan be stored and disposed of?

How to Store and Dispose of Perfan?

Perfan (Enoximone) concentrate for solution for injection must be stored and handled according to specific regulatory requirements to ensure product integrity and safety.

Storage Requirements

Temperature Constraint: The unopened concentrate must be stored at a temperature not exceeding 30 C.
Protection: The medicine must be kept in its original container to protect it from light.
Child Safety: Perfan must be stored out of the sight and reach of children.

Stability and Handling

Since Perfan is a concentrate that requires dilution, the resulting solution must be used immediately after preparation and cannot be stored. This is a mandatory stability constraint outlined in official labeling.

Disposal

Disposal of any unused product or waste material must follow local requirements. For discarding unused or expired medicines, using a drug take-back program is the disposal method preferred by health authorities when one is available.

Perfan